A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2016-06-03
Target enrollment:
Participant gender:
Summary
The purpose of this study was to investigate the effect of bexagliflozin in lowering
hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM). Bexagliflozin
is an orally administered drug for the treatment of T2DM and is classified as a Sodium
Glucose co-Transporter 2 (SGLT2) Inhibitor. This study was to enroll both treatment naive and
those subjects previously treated with one oral hypoglycemic agent (OHA). Approximately 320
subjects eligible for randomization was to receive bexagliflozin tablets, 5, 10, 20 mg or
placebo, once daily for 12 weeks in an outpatient setting.